Prostate cancer remains one of the leading causes of cancer‐related death in the world.
There have been significant advances in chemotherapy, hormonal therapy and targeted …

Theranostics in men with metastatic castration-resistant prostate cancer (mCRPC) has been
developed to target bone and the tumor itself. Currently, bone-directed targeted alpha …

Simple Summary Metastatic prostate cancer has traditionally been treated with a
combination of hormonal and chemotherapy regimens. With the recent FDA approval of …

Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PSMA-RLT) with
lutetium-177 (177 Lu-PSMA) has been used in metastatic castrate-resistant prostate cancer …

Background Life expectancy of patients with metastatic castration-resistant prostate cancer
(mCRPC) is still limited despite several systemic treatments. Within five years after diagnosis …

Aims There is a controversy as to the relative efficacy of 177 Lu prostate specific membrane
antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with …

228 Background: Lutetium-177 (177Lu)-PSMA-617 (LuPSMA) is a radiolabelled small
molecule that binds with high affinity to prostate specific membrane antigen (PSMA) …

For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival
benefit of classic treatment options with chemotherapy and drugs targeting androgen …

177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …

Introduction Metastatic castrate resistant prostate cancer (mCPRC) remains an aggressive
form of prostate cancer that no longer responds to traditional hormonal treatment alone …